Spyglass Pharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
SpyGlass Pharma, Inc. reports significant progress in its BIM-IOL System for glaucoma, initiating two Phase 3 clinical trials and completing a successful IPO in early 2026, despite ongoing financial losses.